HMOX1 and metabolic dysfunction-associated steatohepatitis: In this respect, PBP‐NPs containing HO‐1 inducers have a strong potential as safe and efficient nanotherapeutics for curing and preventing obesity, obesity‐induced metabolic syndromes, and NASH in future clinical studies.